Abstract
Cytokines play a critical role in coordinating and amplifying a host immune response to infection. The normal pattern of localized and systemic release of proinflammatory and anti-inflammatory cytokines varies on the basis of the disease process. A dysregulated cytokine response can lead to a hyper-inflammatory condition called a cytokine storm. This is believed to contribute to the pathophysiology of sepsis and septic shock, a condition carrying high morbidity and mortality in critically ill patients. Extracorporeal cytokine hemoadsorption is an emerging technology utilized in the treatment of dysregulated inflammatory states such as sepsis, although there is a paucity of clinical evidence supporting its outcomes benefits. We assess the peer-reviewed literature relating to cytokine hemoadsorption in the context of sepsis and suggest areas of future research incorporating this novel technology.
References
1.
Polat G, Ugan RA, Cadirci E, Halici Z: Sepsis and septic shock: current treatment strategies and new approaches. Eurasian J Med 2017; 49: 53–58.
2.
Dinarello CA: Historical insights into cytokines. Eur J Immunol 2007; 37(suppl 1):S34–S45.
3.
Chousterman BG, Swirski FK, Weber GF: Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol 2017; 39: 517–528.
4.
Gerlach H: Agents to reduce cytokine storm. F1000Res 2016; 5: 2909.
5.
Andersson U, Tracey KJ: Reflex principles of immunological homeostasis. Annu Rev Immunol 2012; 30: 313–335.
6.
Steltzer H, Grieb A, Mostafa K, Berger R: Use of CytoSorb in traumatic amputation of the forearm and severe septic shock. Case Rep Crit Care 2017; 2017: 8747616.
7.
Matsuda K, Moriguchi T, Harii N, Goto J: Comparison of efficacy between continuous hemodiafiltration with a PMMA membrane hemofilter and a PAN membrane hemofilter in the treatment of a patient with septic acute renal failure. Transfus Apher Sci 2009; 40: 49–53.
8.
Hosgood SA, Moore T, Kleverlaan T, Adams T, Nicholson ML: Haemoadsorption reduces the inflammatory response and improves blood flow during ex vivo renal perfusion in an experimental model. J Transl Med 2017; 15: 216.
9.
Hotchkiss RS, Opal S: Immunotherapy for sepsis – a new approach against an ancient foe. N Engl J Med 2010; 363: 87–89.
10.
van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frolich M: Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998; 351: 950–953.
11.
Allen ML, Hoschtitzky JA, Peters MJ, Elliott M, Goldman A, James I, Klein NJ: Interleukin-10 and its role in clinical immunoparalysis following pediatric cardiac surgery. Crit Care Med 2006; 34: 2658–2665.
12.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801–810.
13.
Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13: 260–268.
14.
Ferrara JL, Abhyankar S, Gilliland DG: Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc 1993; 25: 1216–1217.
15.
Aikawa N: [Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults]. Nihon Geka Gakkai Zasshi 1996; 97: 771–777.
16.
Weaver LK, Behrens EM: Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis. Curr Treatm Opt Rheumatol 2017; 3: 33–48.
17.
Weaver LK, Behrens EM: Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Curr Opin Rheumatol 2014; 26: 562–569.
18.
Oberholzer A, Souza SM, Tschoeke SK, Oberholzer C, Abouhamze A, Pribble JP, Moldawer LL: Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 2005; 23: 488–493.
19.
Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC; GenIMS Investigators: Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (GenIMS) study. Arch Intern Med 2007; 167: 1655–1663.
20.
Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A, Zanc V, Carstina D, Oltean M: Multiplex cytokine profiling in patients with sepsis. APMIS 2011; 119: 155–163.
21.
Gouel-Chéron A, Allaouchiche B, Guignant C, Davin F, Floccard B, Monneret G, Group A: Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma. PLoS One 2012; 7: e33095.
22.
Bonavia A, Miller L, Kellum JA, Singbartl K: Hemoadsorption corrects hyperresistinemia and restores anti-bacterial neutrophil function. Intensive Care Med Exp 2017; 5: 36.
23.
Singbartl K, Miller L, Ruiz-Velasco V, Kellum JA: Reversal of acute kidney injury-induced neutrophil dysfunction: a critical role for resistin. Crit Care Med 2016; 44:e492–501.
24.
Bellomo R, Honore PM, Matson J, Ronco C, Winchester J: Extracorporeal blood treatment (EBT) methods in SIRS/Sepsis. Int J Artif Organs 2005; 28: 450–458.
25.
Cantaluppi V, Weber V, Lauritano C, Figliolini F, Beltramo S, Biancone L, De Cal M, Cruz D, Ronco C, Segoloni GP, Tetta C, Camussi G: Protective effect of resin adsorption on septic plasma-induced tubular injury. Crit Care 2010; 14:R4.
26.
Russell JA: Management of sepsis. N Engl J Med 2006; 355: 1699–1713.
27.
Angstwurm MW, Engelmann L, Zimmermann T, Lehmann C, Spes CH, Abel P, Strauss R, Meier-Hellmann A, Insel R, Radke J, Schüttler J, Gärtner R: Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 2007; 35: 118–126.
28.
Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM: Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010; 38: 72–83.
29.
Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL, ACCESS Study Group: Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013; 309: 1154–1162.
30.
Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The soluble TNF receptor sepsis study group. N Engl J Med 1996; 334: 1697–1702.
31.
Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733–742.
32.
Opal SM, Fisher CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The interleukin-1 receptor antagonist sepsis investigator group. Crit Care Med 1997; 25: 1115–1124.
33.
Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der Auwera P; Lenercept Study Group: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29: 503–510.
34.
Lorente JA, Marshall JC: Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 2005; 24(suppl 1): 107–119.
35.
Yates JW, Das S, Mainwaring G, Kemp J: Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-α polyclonal fragment antibody AZD9773 in patients with severe sepsis. J Pharmacokinet Pharmacodyn 2012; 39: 591–599.
36.
Aikawa N, Takahashi T, Fujimi S, Yokoyama T, Yoshihara K, Ikeda T, Sadamitsu D, Momozawa M, Maruyama T: A Phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock. J Infect Chemother 2013; 19: 931–940.
37.
Bernard GR, Francois B, Mira JP, Vincent JL, Dellinger RP, Russell JA, Larosa SP, Laterre PF, Levy MM, Dankner W, Schmitt N, Lindemann J, Wittebole X: Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*. Crit Care Med 2014; 42: 504–511.
38.
Rice TW, Wheeler AP, Morris PE, Paz HL, Russell JA, Edens TR, Bernard GR: Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med 2006; 34: 2271–2281.
39.
Qiu P, Cui X, Sun J, Welsh J, Natanson C, Eichacker PQ: Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. Crit Care Med 2013; 41: 2419–2429.
40.
Lv S, Han M, Yi R, Kwon S, Dai C, Wang R: Anti-TNF-α therapy for patients with sepsis: a systematic meta-analysis. Int J Clin Pract 2014; 68: 520–528.
41.
Ronco C, Brendolan A, d'Intini V, Ricci Z, Wratten ML, Bellomo R: Coupled plasma filtration adsorption: rationale, technical development and early clinical experience. Blood Purif 2003; 21: 409–416.
42.
Bellomo R, Tetta C, Brendolan A, Ronco C: Coupled plasma filtration adsorption. Blood Purif 2002; 20: 289–292.
43.
Bellomo R, Tetta C, Ronco C: Coupled plasma filtration adsorption. Intensive Care Med 2003; 29: 1222–1228.
44.
Villa G, Neri M, Bellomo R, Cerda J, De Gaudio AR, De Rosa S, Garzotto F, Honore PM, Kellum J, Lorenzin A, Payen D, Ricci Z, Samoni S, Vincent JL, Wendon J, Zaccaria M, Ronco C; Nomenclature Standardization Initiative (NSI) Alliance: Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications. Crit Care 2016; 20: 283.
45.
Cruz D, Bellomo R, Kellum JA, de Cal M, Ronco C: The future of extracorporeal support. Crit Care Med 2008; 36:S243–252.
46.
Bellomo R, Tipping P, Boyce N: Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 1993; 21: 522–526.
47.
Grootendorst AF, van Bommel EF: The role of hemofiltration in the critically-ill intensive care unit patient: present and future. Blood Purif 1993; 11: 209–223.
48.
Hirasawa H, Sugai T, Ohtake Y, Oda S, Matsuda K, Kitamura N: Blood purification for prevention and treatment of multiple organ failure. World J Surg 1996; 20: 482–486.
49.
Hattori N, Oda S: Cytokine-adsorbing hemofilter: old but new modality for septic acute kidney injury. Renal Replacement Therapy 2016; 2: 1–8.
50.
Cole L, Bellomo R, Davenport P, Tipping P, Ronco C: Cytokine removal during continuous renal replacement therapy: an ex vivo comparison of convection and diffusion. Int J Artif Organs 2004; 27: 388–397.
51.
Winchester JF, Kellum JA, Ronco C, Brady JA, Quartararo PJ, Salsberg JA, Levin NW: Sorbents in acute renal failure and the systemic inflammatory response syndrome. Blood Purif 2003; 21: 79–84.
52.
Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P, Network VNARFT: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359: 7–20.
53.
Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet JL, Dewitte A, Flamens C, Pujol W, Grandoulier AS, Fleureau C, Jacobs R, Broux C, Floch H, Branchard O, Franck S, Rozé H, Collin V, Boer W, Calderon J, Gauche B, Spapen HD, Janvier G, Ouattara A: High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013; 39: 1535–1546.
54.
Winchester JF, Ronco C, Brady JA, Cowgill LD, Salsberg J, Yousha E, Choquette M, Albright R, Clemmer J, Davankov V, Tsyurupa M, Pavlova L, Pavlov M, Cohen G, Horl W, Gotch F, Levin NW: The next step from high-flux dialysis: application of sorbent technology. Blood Purif 2002; 20: 81–86.
55.
Ronco C: Sorbents: from bench to bedside. Can we combine membrane separation processes and adsorbent based solute removal? Int J Artif Organs 2006; 29: 819–822.
56.
Morgera S, Haase M, Kuss T, Vargas-Hein O, Zuckermann-Becker H, Melzer C, Krieg H, Wegner B, Bellomo R, Neumayer HH: Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006; 34: 2099–2104.
57.
Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Davenport P, Morgera S, Goehl H, Storr M, Boyce N, Neumayer HH: Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis 2007; 50: 296–304.
58.
Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E; Hemofiltration and Sepsis Group of the Collège National de Réanimation et de Médecine d'Urgence des Hôpitaux extra-Universitaires: Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009; 37: 803–810.
59.
Chung KK, Coates EC, Smith DJ, Karlnoski RA, Hickerson WL, Arnold-Ross AL, Mosier MJ, Halerz M, Sprague AM, Mullins RF, Caruso DM, Albrecht M, Arnoldo BD, Burris AM, Taylor SL, Wolf SE; Randomized controlled Evaluation of high-volume hemofiltration in adult burn patients with Septic shoCk and acUte kidnEy injury (RESCUE) Investigators: High-volume hemofiltration in adult burn patients with septic shock and acute kidney injury: a multicenter randomized controlled trial. Crit Care 2017; 21: 289.
60.
Borthwick EM, Hill CJ, Rabindranath KS, Maxwell AP, McAuley DF, Blackwood B: High-volume haemofiltration for sepsis in adults. Cochrane Database Syst Rev 2017; 1: CD008075.
61.
Clark WR, Gao D, Lorenzin A, Ronco C: Membranes and Sorbents. Contrib Nephrol 2018; 194: 70–79.
62.
Ronco C, Brendolan A, Dan M, Piccinni P, Bellomo R, Wratten ML, Inguaggiato P, Tetta C: Use of sorbents in acute renal failure and sepsis. Contrib Nephrol 2001: 180–193.
63.
Ronco C, Brendolan A, Dan M, Piccinni P, Bellomo R, De Nitti C, Inguaggiato P, Tetta C: Adsorption in sepsis. Kidney Int Suppl 2000; 76:S148–S155.
64.
Clark WR, Ferrari F, La Manna G, Ronco C: Extracorporeal sorbent technologies: basic concepts and clinical application. Contrib Nephrol 2017; 190: 43–57.
65.
Ronco C, Tetta C: Extracorporal blood purification: more than diffusion and convection. Does this help? Curr Opin Crit Care 2007; 13: 662–667.
66.
Tetta C, Bellomo R, Formica M, Livigni S, Mariano F, Wratten ML, Carraro G, Ronco C: Use of adsorbents in ARF therapy. Contrib Nephrol 2002: 181–188.
67.
Sunavala JD, Mascarenhas JM: Endotoxin hemadsorption in septic shock. Indian J Crit Care Med 2014; 18: 773–774.
68.
Anspach FB: Endotoxin removal by affinity sorbents. J Biochem Biophys Methods 2001; 49: 665–681.
69.
Clinical Benefits- PMX, 2018. http://www.spectraldx.com/pmx-benefits.html (Last accessed 2018).
70.
Shimizu T, Miyake T, Tani M: History and current status of polymyxin B-immobilized fiber column for treatment of severe sepsis and septic shock. Ann Gastroenterol Surg 2017; 1: 105–113.
71.
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301: 2445–2452.
72.
Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, Pottecher J, Joannes-Boyau O, Martin-Lefevre L, Jabaudon M, Mimoz O, Coudroy R, Ferrandière M, Kipnis E, Vela C, Chevallier S, Mallat J, Robert R; ABDOMIX Group: Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 2015; 41: 975–984.
73.
Shoji H: Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 2003; 7: 108–114.
74.
Aucella F, Vigilante M, Gesuete A: Review: the effect of polymethylmethacrylate dialysis membranes on uraemic pruritus. NDT Plus 2010; 3(suppl 1):i8-i11.
75.
Cohen G, Rudnicki M, Schmaldienst S, Hörl WH: Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients. Nephrol Dial Transplant 2002; 17: 879–883.
76.
Abe R, Oda S, Shinozaki K, Hirasawa H: Continuous hemodiafiltration using a polymethyl methacrylate membrane hemofilter for severe acute pancreatitis. Contrib Nephrol 2010; 166: 54–63.
77.
Nakada TA, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe R, Hirasawa H: Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med 2008; 14: 257–263.
78.
Doi K, Iwagami M, Yoshida E, Marshall MR: Associations of polyethylenimine-coated AN69ST membrane in continuous renal replacement therapy with the intensive care outcomes: observations from a claims database from Japan. Blood Purif 2017; 44: 184–192.
79.
Baxter International, Inc. oXiris. http://www.smartmedical.ro/public/data_files/content/files/oxiris_sales_brochure_high-miccompressed.pdf (Last accessed July 12, 2018).
80.
Shum HP, Chan KC, Kwan MC, Yan WW: Application of endotoxin and cytokine -adsorption haemofilter in septic acute kidney injury due to gram-negative bacterial infection. Hong Kong Med J 2013; 19: 491–497.
81.
De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH: Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10: 846–853.
82.
Rimmele T, Assadi A, Cattenoz M, Desebbe O, Lambert C, Boselli E, Goudable J, Etienne J, Chassard D, Bricca G, Allaouchiche B: High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant 2009; 24: 421–427.
83.
Kogelmann K, Jarczak D, Scheller M, Drüner M: Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care 2017; 21: 74.
84.
Malard B, Lambert C, Kellum JA: In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp 2018; 6: 12.
85.
Cytosorbent Corporation, CytoSorb Product Safety. http://cytosorb-therapy.com/the-therapy/product_safety/ (Last accessed July 12, 2018).
86.
Cytosorbent Corporation, CytoSorb Fields of Application. http://cytosorb-therapy.com/the-adsorber/faq_fields-of-application/ (Last accessed July 12, 2018).
87.
Cytosorbents. CytoSorb – The Therapy, 2018. http://cytosorb-therapy.com/the-therapy/ (Last accessed July 5, 2018).
88.
Cytosorbents. Setup of CytoSorb – Different options, 2018. http://cytosorb-therapy.com/the-adsorber/setup/ (Last accessed July 4, 2018).
89.
Short Set-up Guide – Hemoperfusion set-up, Cytosorbents Europe GmbH.
90.
CytoSorbents Corporation, CytoSorb: Broad Cytokine and Toxin Reduction to Control Deadly Inflammation. http://cytosorbents.com/products/cyto-sorb/ (Last accessed July 12, 2018).
91.
Cytosorbents. The Adsorber – CytoSorb, 2018. http://cytosorb-therapy.com/the-adsorber/ (Last accessed July 4, 2018).
92.
Gruda MC, Ruggeberg KG, O'Sullivan P, Guliashvili T, Scheirer AR, Golobish TD, Capponi VJ, Chan PP: Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads. PLoS One 2018; 13:e0191676.
94.
Cytosorbents Corporation, CytoSorb Literature Database, 2018. https://literature.CytoSorb.com (Last accessed July 12, 2018).
95.
Filková M, Haluzík M, Gay S, Senolt L: The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009; 133: 157–170.
96.
Koch A, Gressner OA, Sanson E, Tacke F, Trautwein C: Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit Care 2009; 13:R95.
97.
Song M, Winchester J, Albright RL, Capponi VJ, Choquette MD, Kellum JA: Cytokine removal with a novel adsorbent polymer. Blood Purif 2004; 22: 428–434.
98.
Kellum JA, Song M, Venkataraman R: Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004; 32: 801–805.
99.
Peng ZY, Carter MJ, Kellum JA: Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 2008; 36: 1573–1577.
100.
Zhang J, Peng Z, Maberry D, Volpe J, Kimmel JD, Federspiel WJ, Kellum JA: Effects of hemoadsorption with a novel adsorbent on sepsis: in vivo and in vitro study. Blood Purif 2015; 39: 239–245.
101.
Peng ZY, Wang HZ, Carter MJ, Dileo MV, Bishop JV, Zhou FH, Wen XY, Rimmelé T, Singbartl K, Federspiel WJ, Clermont G, Kellum JA: Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int 2012; 81: 363–369.
102.
Taniguchi T: Cytokine adsorbing columns. Contrib Nephrol 2010; 166: 134–141.
103.
Kobe Y, Oda S, Matsuda K, Nakamura M, Hirasawa H: Direct hemoperfusion with a cytokine-adsorbing device for the treatment of persistent or severe hypercytokinemia: a pilot study. Blood Purif 2007; 25: 446–453.
104.
Friesecke S, Stecher SS, Gross S, Felix SB, Nierhaus A: Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs 2017; 20: 252–259.
105.
Trager K, Fritzler D, Fischer G, Schroder J, Skrabal C, Liebold A, Reinelt H: Treatment of post-cardiopulmonary bypass SIRS by hemoadsorption: a case series. Int J Artif Organs 2016; 39: 141–146.
106.
Bernardi MH, Rinoesl H, Dragosits K, Ristl R, Hoffelner F, Opfermann P, Lamm C, Preißing F, Wiedemann D, Hiesmayr MJ, Spittler A: Effect of hemoadsorption during cardiopulmonary bypass surgery – a blinded, randomized, controlled pilot study using a novel adsorbent. Crit Care 2016; 20: 96.
107.
Schadler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, Marx G, Putensen C, Spies C, Jorres A, Quintel M, Engel C, Kellum JA, Kuhlmann MK: The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS One 2017; 12:e0187015.
108.
Chung LP, Waterer GW: Genetic predisposition to respiratory infection and sepsis. Crit Rev Clin Lab Sci 2011; 48: 250–268.
109.
Cornell TT, Wynn J, Shanley TP, Wheeler DS, Wong HR: Mechanisms and regulation of the gene-expression response to sepsis. Pediatrics 2010; 125: 1248–1258.
110.
Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riché F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut JF: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282: 561–568.
111.
Calvano JE, Um JY, Agnese DM, Hahm SJ, Kumar A, Coyle SM, Calvano SE, Lowry SF: Influence of the TNF-alpha and TNF-beta polymorphisms upon infectious risk and outcome in surgical intensive care patients. Surg Infect (Larchmt) 2003; 4: 163–169.
112.
Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC: The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. Crit Care Med 2014; 42: 1714–1721.
113.
Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD, 2nd, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306: 2594–2605.
114.
Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138–150.
115.
Delano MJ, Ward PA: The immune system’s role in sepsis progression, resolution, and long-term outcome. Immunol Rev 2016; 274: 330–353.
116.
Markwart R, Condotta SA, Requardt RP, Borken F, Schubert K, Weigel C, Bauer M, Griffith TS, Förster M, Brunkhorst FM, Badovinac VP, Rubio I: Immunosuppression after sepsis: systemic inflammation and sepsis induce a loss of naïve T-cells but no enduring cell-autonomous defects in T-cell function. PLoS One 2014; 9:e115094.
117.
Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W: Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3: 678–681.
118.
Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, Bauer M, Riedemann NC: The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 2011; 15:R183.
119.
Drutskaya MS, Efimov GA, Kruglov AA, Nedospasov SA: Can we design a better anti-cytokine therapy? J Leukoc Biol 2017; 102: 783–790.
120.
Rogler G, Biedermann L, Scharl M: Anti-cytokine strategies beyond anti-tumour necrosis factor-α therapy: pathophysiology and clinical implications. Dig Dis 2017; 35: 5–12.
121.
van der Meer JW, Popa C, Netea MG: Side effects of anticytokine strategies. Neth J Med 2005; 63: 78–80.
122.
Garbers C, Aparicio-Siegmund S, Rose-John S: The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol 2015; 34: 75–82.
123.
Rogez-Kreuz C, Manéglier B, Martin M, Dereuddre-Bosquet N, Martal J, Dormont D, Clayette P: Involvement of IL-6 in the anti-human immunodeficiency virus activity of IFN-tau in human macrophages. Int Immunol 2005; 17: 1047–1057.
124.
Schmidt EM, Davies M, Mistry P, Green P, Giddins G, Feldmann M, Stoop AA, Brennan FM: Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures. Arthritis Rheum 2013; 65: 2262–2273.
125.
McCann FE, Perocheau DP, Ruspi G, Blazek K, Davies ML, Feldmann M, Dean JL, Stoop AA, Williams RO: Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol 2014; 66: 2728–2738.
126.
Fischer R, Maier O, Siegemund M, Wajant H, Scheurich P, Pfizenmaier K: A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS One 2011; 6:e27621.
127.
Okubo Y, Torrey H, Butterworth J, Zheng H, Faustman DL: Treg activation defect in type 1 diabetes: correction with TNFR2 agonism. Clin Transl Immunology 2016; 5:e56.
128.
Rusai K, Huang H, Sayed N, Strobl M, Roos M, Schmaderer C, Heemann U, Lutz J: Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury. Transpl Int 2008; 21: 572–580.
129.
Multhoff G, Molls M, Radons J: Chronic inflammation in cancer development. Front Immunol 2011; 2: 98.
130.
CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery – Full Text View – ClinicalTrials.gov, 2018. https://clinicaltrials.gov/ct2/show/NCT03384875 (Last accessed June 28, 2018).
131.
Pomare Montin D, Ankawi G, Lorenzin A, Neri M, Caprara C, Ronco C: Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion. Blood Purif 2018; 46: 187–195.
132.
Cytosorbents. Cytosorb registry. n.d. http://www.cytosorb-registry.org/?lang=en (Last accessed June 14, 2018).
133.
Friesecke S, Träger K, Schittek GA, Molnar Z, Bach F, Kogelmann K, Bogdanski R, Weyland A, Nierhaus A, Nestler F, Olboeter D, Tomescu D, Jacob D, Haake H, Grigoryev E, Nitsch M, Baumann A, Quintel M, Schott M, Kielstein JT, Meier-Hellmann A, Born F, Schumacher U, Singer M, Kellum J, Brunkhorst FM: International registry on the use of the CytoSorb® adsorber in ICU patients: study protocol and preliminary results. Med Klin Intensivmed Notfmed 2017, Epub ahead of print.
134.
Nemeth E, Kovacs E, Racz K, Soltesz A, Szigeti S, Kiss N, Csikos G, Koritsanszky KB, Berzsenyi V, Trembickij G, Fabry S, Prohaszka Z, Merkely B, Gal J: Impact of intraoperative cytokine adsorption on outcome of patients undergoing orthotopic heart transplantation-an observational study. Clin Transplant 2018; 32:e13211.
135.
Trager K, Skrabal C, Fischer G, Datzmann T, Schroeder J, Fritzler D, Hartmann J, Liebold A, Reinelt H: Hemoadsorption treatment of patients with acute infective endocarditis during surgery with cardiopulmonary bypass – a case series. Int J Artif Organs 2017; 40: 240–249.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
